EU stamps his­toric OK on blue­bird’s gene ther­a­py for β-tha­lassemia — now sit back and wait for the price

6 years ago
R&D
Cell/Gene Tx

Eye­Gate surges on FDA nod to start piv­otal study; Alde­vron to build gene ther­a­py man­u­fac­tur­ing cam­pus in Far­go, N.D.

6 years ago
News Briefing

J&J, Gen­mab strength­en case for Darza­lex in front­line mul­ti­ple myelo­ma with fresh slate of PhI­II da­ta

6 years ago
R&D

Ma­ligned ex-MiMedx chief Pe­tit wants back on the board — wound care com­pa­ny tells share­hold­ers to say no way

6 years ago
People

Quest for safe mus­carinic re­cep­tor ag­o­nists to tack­le dis­as­ter prone CNS field steers Karuna to $75M IPO

6 years ago
Financing

#AS­CO19: Am­gen grows more con­fi­dent in KRAS G12C drug with a pos­i­tive snap­shot for lung can­cer — shares spike

6 years ago
R&D

About the re­designed End­points News

6 years ago
Publisher's note

#AS­CO19: Clay Sie­gall is ready to take a big leap for­ward as Seat­tle Ge­net­ics’ next top drug prospect steps on­to ...

6 years ago
R&D

Vi­cal finds way out of R&D woes via re­verse merg­er with der­ma­tol­ogy biotech Brick­ell

6 years ago
Deals

Shkre­li set­tles in­to his new prison digs in Penn­syl­va­nia with a $30M+ law­suit against for­mer Retrophin col­leagues

6 years ago
People

#AS­CO19 roundup: As­traZeneca, Mer­ck score an­oth­er Lyn­parza hit

6 years ago
R&D
Pharma

#AS­CO19: Am­gen shows off their lat­est BC­MA BiTE up­date with plans to hus­tle ahead as ri­vals jos­tle for po­si­tion

6 years ago
R&D

#AS­CO19: Strug­gling Nek­tar braves a tough crowd to of­fer up 4 new CRs for skin can­cer drug

6 years ago
R&D

#AS­CO19: Sanofi sets the stage for a late ar­rival of their mul­ti­ple myelo­ma drug isat­ux­imab — with J&J and Gen­mab ...

6 years ago
R&D

#AS­CO19: Hey Pfiz­er, No­var­tis is go­ing af­ter your block­buster can­cer fran­chise — and they have pos­i­tive OS da­ta

6 years ago
R&D
Pharma

#AS­CO19: Mer­ck’s PD-1 star Keytru­da il­lus­trates just how pow­er­ful it can be over 5 years — with plen­ty of room ...

6 years ago
R&D
Pharma

Up­dat­ed: Al­ny­lam pro­motes long­time ex­ec Kevin FitzGer­ald to CSO; In­tel­lia Ther­a­peu­tics brings on Lau­ra Sepp-Loren­zi­no

6 years ago
Peer Review

Fast mov­ing Chi­nese reg­u­la­tors wave third home­grown PD-1 to mar­ket

6 years ago
China

Trade war, CFIUS in­ter­ven­tions force a shift in strat­e­gy at Fo­s­un — sig­nal­ing some big po­ten­tial prob­lems for US ...

6 years ago
China
Pharma

Turn­ing Point tracks an im­pres­sive ORR rate in NSCLC — but shares skid low­er on sec­ond look

6 years ago
R&D

Luck and uni­corns? Who needs that? San­té Ven­tures’ new $250M fund is look­ing for biotech up­starts

6 years ago
Financing

Aslan dou­bles down on CSL drug, plots long­shot ri­val­ry with Dupix­ent in atopic der­mati­tis

6 years ago
R&D

Io­vance comes back with an­oth­er up­beat can­cer tri­al up­date as #AS­CO19 cur­tain rais­er

6 years ago
R&D

Part­nered with Genen­tech and Mi­crosoft, this biotech be­lieves it can lever­age its knowl­edge of the im­mune sys­tem in­to ...

6 years ago
Financing
First page Previous page 929930931932933934935 Next page Last page
A service from the Financial Times